Physician profile
Katherine Egan
NPI 1386123313
$3,012.59
in general payments reported to CMS, 2019-2025
44 companies · $978 in 2025
The $978 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,011 · 2022: $210 · 2023: $189 · 2024: $624 · 2025: $978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,791.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $249.04 | 2021-2025 | |
| Novocure INC. | $220.04 | 2022-2025 | Optune, Optune Gio |
| Biogen, INC. | $213.47 | 2022-2025 | Vumerity, Tysabri |
| Ani Pharmaceuticals, INC. | $178.28 | 2023-2025 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals Lp | $149.83 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.96 | 2021 | |
| Eisai INC. | $135.78 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $134.15 | 2021-2025 | Austedo Xr, Austedo Xr |
| Glaxosmithkline, LLC. | $129.79 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.37 | 2021 | |
| Silk Road Medical, INC. | $87.55 | 2022 | |
| Lilly USA, LLC | $87.21 | 2024-2025 | Kisunla, Amyvid, Reyvow |
| Inspire Medical Systems, INC. | $85.39 | 2025 | Inspire |
| Actelion Pharmaceuticals US, INC. | $68.57 | 2021 | |
| Insmed, INC. | $65.46 | 2021 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $61.04 | 2023-2025 | Ultomiris, Soliris |
| Aucta Pharmaceuticals, INC. | $55.22 | 2024-2025 | Motpoly Xr |
| Csl Behring | $54.80 | 2024 | Hizentra |
| Lundbeck LLC | $53.64 | 2024-2025 | Vyepti |
| Vanda Pharmaceuticals INC. | $52.75 | 2024-2025 | Ponvory |
| Argenx US, INC. | $49.41 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Servier Pharmaceuticals LLC | $48.12 | 2024-2025 | |
| Pfizer INC. | $46.81 | 2023-2025 | |
| Grifols USA, LLC | $46.44 | 2021 | |
| Mylan Specialty L.P. | $41.66 | 2021 | |
| United Therapeutics Corporation | $37.21 | 2021 | |
| Acadia Pharmaceuticals INC | $36.30 | 2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $36.06 | 2025 | |
| Genentech USA, INC. | $34.64 | 2025 | Ocrevus Zunovo |
| Ucb, INC. | $32.58 | 2024-2025 | Rystiggo, Briviact |
| Medtronic, INC. | $28.53 | 2024 | Intellis Adaptivestim |
| Philips North America LLC | $23.89 | 2021 | |
| Springworks Therapeutics, INC. | $19.60 | 2025 | Gomekli |
| Merz Pharmaceuticals, LLC | $19.05 | 2025 | Xeomin |
| Avadel Cns Pharmaceuticals, LLC | $18.70 | 2024 | Lumryz |
| Advanced Respiratory, INC | $18.67 | 2021 | |
| Amylyx Pharmaceuticals, INC. | $17.75 | 2023 | Relyvrio |
| Axsome Therapeutics, INC. | $17.33 | 2025 | Sunosi |
| Catalyst Pharmaceuticals, INC. | $16.81 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $16.51 | 2023 | Sancuso |
| Mallinckrodt Hospital Products INC. | $16.07 | 2021 | |
| Amgen INC. | $16.05 | 2024 | Uplizna |
| Octapharma USA, INC. | $15.41 | 2024 | Panzyga |
| Jazz Pharmaceuticals INC. | $14.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Egan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.